| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7250176 | US ANTIBIOTICS | Method of treating a bacterial infection |
Apr, 2020
(4 years ago) | |
| US6783773 | US ANTIBIOTICS | Composition comprising amoxicillin and potassium clavulanate |
Apr, 2020
(4 years ago) | |
| US7217430 | US ANTIBIOTICS | Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan |
Apr, 2020
(4 years ago) | |
| US6878386 | US ANTIBIOTICS | Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate |
Apr, 2020
(4 years ago) | |
| US6746692 | US ANTIBIOTICS | Modified release pharmaceutical formulation comprising amoxycillin |
Apr, 2020
(4 years ago) | |
Augmentin Xr is owned by Us Antibiotics.
Augmentin Xr contains Amoxicillin; Clavulanate Potassium.
Augmentin Xr has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Augmentin Xr are:
- US7250176
- US6783773
- US7217430
- US6878386
- US6746692
Augmentin Xr was authorised for market use on 25 September, 2002.
Augmentin Xr is available in tablet, extended release;oral dosage forms.
Augmentin Xr can be used as mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & s. pneumoniae with reduced susceptibility to penicillin (mic=2mc/ml).
The generics of Augmentin Xr are possible to be released after 04 April, 2020.
Drugs and Companies using AMOXICILLIN; CLAVULANATE POTASSIUM ingredient
Market Authorisation Date: 25 September, 2002
Treatment: Mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & s. pneumoniae with reduced susc...
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUGMENTIN XR family patents
